Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 9/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | MC4R | P32245 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13699617 | 0.88 | MDM2 (0.40) | MDM2CNR1MC4RHTR2CDRD2 | |
| SCHEMBL13699618 | 0.88 | MDM2 (0.40) | MDM2CNR1MC4RHTR2CDRD2 | |
| SCHEMBL13699615 | 0.81 | MDM2 (0.39) | MDM2CNR1MC4RHTR2C | |
| SCHEMBL13699637 | 0.78 | MDM2 (0.47) | MDM2CNR1 | |
| SCHEMBL13699661 | 0.75 | MDM2 (0.40) | MDM2MC4RHTR2CDRD2DRD4 | |
| SCHEMBL13699636 | 0.72 | MDM2 (0.38) | MDM2MC4RHTR2CDRD2DRD4 | |
| SCHEMBL11958488 | 0.72 | MDM2 (0.54) | MDM2CNR1 | |
| SCHEMBL11958425 | 0.72 | MDM2 (0.61) | MDM2CNR1 | |
| SCHEMBL11957715 | 0.71 | MDM2 (0.56) | MDM2CNR1HPGD | |
| SCHEMBL13699595 | 0.70 | MDM2 (0.41) | MDM2CNR1HTR2CDRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | VERNALIS (R&D) (GB) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | CNR2, CNR1, ALK | MDM2 2997/4885CNR1 2/4885MC4R 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.